Table 1 Patient Characteristics, Tumor Survivin Expression, and CD4+ Survivin Specific Precursor Frequency
From: Survivin-specific CD4+ T cells are decreased in patients with survivin-positive myeloma
Age | Disease Characteristics | Durie Salmon Stage | Prior Regimens | Imid Therapy | IMWG Response | High Risk | Survivin IHC* | Survivin mRNA** | Survivin Specific CD4+ Precursor Frequency (% of CD4) |
|---|---|---|---|---|---|---|---|---|---|
67 | IgG lambda | IIB | 1 | yes | VGPR | no | 7 | - | 0.000000 |
46 | IgG lambda | IIIA | 1 | no | PR | no | - | - | 0.000000 |
69 | IgG kappa | IIA | 1 | yes | PR | no | 8 | - | 0.000052 |
67 | Â | IIIA | 2 | yes | Â | yes | 5 | 1.375 | 0.000274 |
64 | IgG kappa | IA | 2 | no | VGPR | yes | 5 | - | 0.000346 |
49 | IgG lambda | IIIB | 1 | yes | VGPR | no | - | - | 0.000349 |
56 | IgG kappa | IIIB | 2 | no | PR | no | 7 | 1.248 | 0.000401 |
46 | IgA kappa | IA | 2 | no | PR | no | 4 | 0.814 | 0.000466 |
57 | IgG kappa | IIIB | 2 | yes | PR | no | 6 | 0.625 | 0.000643 |
69 | IgG kappa | IIIA | 1 | yes | PR | yes | - | - | 0.000798 |
69 | IgG kappa | IA | 1 | no | VGPR | no | - | - | 0.001007 |
62 | IgG lambda | IIIA | 1 | no | PR | no | - | - | 0.001195 |
66 | IgG kappa | IA | 2 | no | PR | yes | 4 | 0.481 | 0.001579 |
74 | IgA lambda | IIIB | 2 | yes | PR | yes | 2 | 0.226 | 0.002250 |
62 | IgG kappa | IIIA | 1 | yes | VGPR | yes | 5 | - | 0.002657 |
50 | lambda light chain | IIA | 1 | no | VGPR | no | - | - | 0.006804 |